Results from a randomized, phase 2 clinical trial show that adding high-dose, intravenous (IV) vitamin C to chemotherapy ...

In the study, 34 patients with stage 4 metastatic pancreatic cancer were randomized ... the UI team also included cancer ...

Pancreatic cancer (PC) remains a formidable challenge in oncology due to its notoriously poor prognosis, often resulting from ...

Pancreatic cancer is the third leading cause of cancer death in the U.S. That’s due in part to the limited testing available for early detection. Now researchers at Johns Hopkins say they’ve made a ...

CD40 agonists have had mixed results in cancer to date, with Roche discontinuing its selicrelumab candidate after ...

Most people erroneously think pancreatic cancer occurs only in older people and that they cannot alter risk. HealthDay News — Most people continue to believe that pancreatic cancer affects only the ...

November is Pancreatic Cancer Awareness Month. Pancreatic cancer is a deadly disease with the highest mortality rate of all ...

Pancreatic cancer (PC) remains a formidable challenge in oncology due to its notoriously poor prognosis, often resulting from late-stage diagnosis. Early detection through effective screening methods ...

A new drug strategy that regulates the tumor immune microenvironment may transform a tumor that resists immunotherapy into a susceptible one, according to a new study.

A randomized, phase 2 clinical trial shows that adding high-dose, intravenous (IV) vitamin C to chemotherapy doubles the overall survival of patients with late-stage metastatic pancreatic cancer from ...